Pharmacists News

• Alert Compounded Semaglutide Overdoses Tied to Hospitalizations The US Food and Drug Administration alerted clinicians, compounders, and patients about adverse events related to compounded semaglutide dosing errors.
  Medscape Medical News, July 26, 2024
• Alert EMA Says Don't Mix Mysimba and Opioid-Containing Meds Existing advice for prescribing the weight loss drugs needs to be strengthened to minimize the risks from interactions, the European drug authority said.
  Medscape Medical News, July 26, 2024
• Alert EU Backs Drug to Relieve Itching in Alagille Syndrome The European Medicines Agency said there were exceptional circumstances for approving Kayfanda to treat pruritus in patients with the rare genetic disorder.
  Medscape Medical News, July 26, 2024
• Alert Anzupgo Approved in Europe for Severe Hand Eczema The drug downregulates immune and inflammatory responses in cells linked to the disease pathology.
  Medscape Medical News, July 26, 2024
• Alert FDA Approves JAK Inhibitor for Alopecia Areata The pivotal phase 3 trials enrolled 1223 adults in the United States, Canada, and Europe.
  Medscape Medical News, July 26, 2024
• Alert EMA Refuses Marketing Authorization for Alzheimer's Drug Leqembi's EU-wide marketing authorization was refused because the drug's effect on delaying cognitive decline does not counterbalance the risk for serious adverse events.
  Medscape Medical News, July 26, 2024
• Alert EMA Backs Oral Drug for Primary Biliary Cholangitis Iqirvo can delay liver fibrosis and cirrhosis in patients with primary biliary cholangitis, the European Medicines Agency decided.
  Medscape Medical News, July 26, 2024
• Tirbanibulin 1% Safe in Extensive Actinic Keratosis The safety and tolerability of tirbanibulin 1% in patients with actinic keratosis over a larger treatment field was confirmed in a phase 3 study.
  Medscape Medical News, July 26, 2024
• Inappropriate NSAID Prescribing Causing Avoidable Harm Prescribing NSAIDs to people at high risk of harm from them has cost more than 6000 years of good health and £31 million for the NHS over the past decade, a study found.
  Medscape News UK, July 26, 2024
• A Woman, a Tuna Steak, and Allergy-like Symptoms Scombroid poisoning resembles an allergic reaction and occurs after eating fish contaminated with histamine.
  Medscape News UK, July 26, 2024
• Bird Flu Infects Three More Colorado Poultry Farm Workers The Colorado Department of Public Health and Environment on Thursday announced three additional human cases of bird flu among poultry farm workers, bringing the total number...
  Reuters Health Information, July 25, 2024
• Newer Shingles Vaccine Tied to Lower Dementia Risk A new study showed a newer recombinant shingles vaccine was linked to a 164-day delay in dementia diagnosis in older adults compared to an older live shingles vaccine.
  Medscape Medical News, July 25, 2024
• AIDS 2024 Twice-Yearly PrEP Gives 'Huge' 100% Protection Final results of the highly anticipated PURPOSE 1 trial of lenacapavir show the shots prevent new infections without many side effects.
  Medscape Medical News, July 25, 2024
• Slow-Release Buprenorphine Safe in Mild OUD Withdrawal Extended-release buprenorphine medication was deemed safe for patients with mild opioid withdrawal.
  Medscape Medical News, July 25, 2024
• EULAR 2024 Taper, Dose Down, Discontinue: Striving for Less Steroid Use Now in the 75th year since the first presentation on the clinical use of glucocorticoids, what consensus has been reached in sparing their use to avoid their many potential adverse effects?
  Medscape Medical News, July 25, 2024
• GRAPPA 2024 MACE Risk Similar Among Biologics for Psoriasis, PsA A retrospective analysis shows no difference in major adverse cardiovascular events (MACE) between TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/IL-23 inhibitors.
  Medscape Medical News, July 25, 2024
• GRAPPA 2024 Adverse Events Differ Between Two Second-Line Psoriasis Rxs Apremilast and deucravacitinib, oral small-molecule drugs approved for treating psoriasis, were linked to different adverse events, and adverse event profiles differed between men and women.
  Medscape Medical News, July 25, 2024
• EULAR 2024 Breaking Rheumatology's Reliance on Steroids: New Strategies Selective GC receptor agonists and modulators and GC plus hydroxysteroid dehydrogenase inhibitor combination therapy are some of the approaches under consideration.
  Medscape Medical News, July 25, 2024
• How Age Affects Teprotumumab Tx in Thyroid Eye Disease Older patients with thyroid eye disease who receive teprotumumab are more likely to require re-treatment.
  Medscape Medical News, July 25, 2024
• Physicians Cite Barriers in Addiction Care: Study Reveals An international research review identifies multiple reasons why doctors say they aren't able to treat substance abuse, including lack of faith that interventions will work.
  Medscape Medical News, July 25, 2024